The market reaction to Friday’s update from Sanofi and partner Regeneron on experimental respiratory drug itepekimab looks overdone, according to Berenberg. Moreover, Sanofi’s pipeline renaissance is ...

[Click here for information about joining the class action] On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Sanofi has been active in the M&A market this year, picking up Dren Bio’s clinical-stage bispecific antibody, DR-0201, for $600 million upfront and another $1.3 billion in milestones.

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

Sanofi (ENXTPA:SAN) announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the ...

Sanofi (ENXTPA:SAN) announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the ...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evaluating itepekimab in ...